The online version of this article (https://doi.org/10.1007/s00125-018-4741-9) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
Marco Colombo and Helen C. Looker contributed equally to the paper.
As part of the Surrogate Markers for Micro- and Macrovascular Hard Endpoints for Innovative Diabetes Tools (SUMMIT) programme we previously reported that large panels of biomarkers derived from three analytical platforms maximised prediction of progression of renal decline in type 2 diabetes. Here, we hypothesised that smaller (n ≤ 5), platform-specific combinations of biomarkers selected from these larger panels might achieve similar prediction performance when tested in three additional type 2 diabetes cohorts.
We used 657 serum samples, held under differing storage conditions, from the Scania Diabetes Registry (SDR) and Genetics of Diabetes Audit and Research Tayside (GoDARTS), and a further 183 nested case–control sample set from the Collaborative Atorvastatin in Diabetes Study (CARDS). We analysed 42 biomarkers measured on the SDR and GoDARTS samples by a variety of methods including standard ELISA, multiplexed ELISA (Luminex) and mass spectrometry. The subset of 21 Luminex biomarkers was also measured on the CARDS samples. We used the event definition of loss of >20% of baseline eGFR during follow-up from a baseline eGFR of 30–75 ml min−1 [1.73 m]−2. A total of 403 individuals experienced an event during a median follow-up of 7 years. We used discrete-time logistic regression models with tenfold cross-validation to assess association of biomarker panels with loss of kidney function.
Twelve biomarkers showed significant association with eGFR decline adjusted for covariates in one or more of the sample sets when evaluated singly. Kidney injury molecule 1 (KIM-1) and β2-microglobulin (B2M) showed the most consistent effects, with standardised odds ratios for progression of at least 1.4 (p < 0.0003) in all cohorts. A combination of B2M and KIM-1 added to clinical covariates, including baseline eGFR and albuminuria, modestly improved prediction, increasing the area under the curve in the SDR, Go-DARTS and CARDS by 0.079, 0.073 and 0.239, respectively. Neither the inclusion of additional Luminex biomarkers on top of B2M and KIM-1 nor a sparse mass spectrometry panel, nor the larger multiplatform panels previously identified, consistently improved prediction further across all validation sets.
Serum KIM-1 and B2M independently improve prediction of renal decline from an eGFR of 30–75 ml min−1 [1.73 m]−2 in type 2 diabetes beyond clinical factors and prior eGFR and are robust to varying sample storage conditions. Larger panels of biomarkers did not improve prediction beyond these two biomarkers.
ESM (PDF 776 kb)125_2018_4741_MOESM1_ESM.pdf
FDA-NIH Biomarker Working Group (2016) BEST (Biomarkers, EndpointS, and other Tools) Resource. Food and Drug Administration (US), Silver Spring (MD)
Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435):685–696. https://doi.org/10.1016/S0140-6736(04)16895-5 CrossRefPubMed
Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145(4):247–254. https://doi.org/10.7326/0003-4819-145-4-200608150-00004 CrossRefPubMed
Welsh BT, Mapes J (2013). An overview of assay quality systems at Myriad RBM. Available from https://myriadrbm.com/quality-control-white-paper/. Accessed June 2016
R Core Team (2017) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
Dickinson JC, Rosenblum H, Hamilton PB (1970) Ion exchange chromatography of the free amino acids in the plasma of infants under 2,500 gm at birth. Pediatrics 45(4):606–613 PubMed
da Fonseca-Wollheim F (1990) Deamidation of glutamine by increased plasma gamma-glutamyltransferase is a source of rapid ammonia formation in blood and plasma specimens. Clin Chem 36(8 Pt 1):1479–1482 PubMed
Lee JE, Gohda T, Walker WH et al (2013) Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1. PLoS One 8(3):e58007. https://doi.org/10.1371/journal.pone.0058007 CrossRefPubMedPubMedCentral
Critselis E, Lambers Heerspink H (2016) Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression. Nephrol Dial Transplant 31:249–254 PubMed
Schutte E, Gansevoort RT, Benner J, et al (2015) Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression. Nephrol Dial Transplant 30 Suppl 4):iv96-iv104
Donadio C, Lucchesi A, Ardini M, Giordani R (2001) Cystatin C, β2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine. J Pharm Biomed Anal 24(5–6):835–842. https://doi.org/10.1016/S0731-7085(00)00550-1 CrossRefPubMed
Yeung CK, Wong KL, Wong WS, Chan KH (1986) β2-Microglobulin and systemic lupus erythematosus. J Rheumatol 13(6):1053–1058 PubMed
Wakabayashi K, Inokuma S, Matsubara E et al (2013) Serum β2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still’s disease. Clin Rheumatol 32(7):999–1005. https://doi.org/10.1007/s10067-013-2220-8 CrossRefPubMed
Kim MK, Yun K-J, Chun HJ et al (2014) Clinical utility of serum β2-microglobulin as a predictor of diabetic complications in patients with type 2 diabetes without renal impairment. Diabetes Metab 40(6):459–465. https://doi.org/10.1016/j.diabet.2014.08.002 CrossRefPubMed
Astor BC, Shafi T, Hoogeveen RC et al (2012) Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis 59(5):653–662. https://doi.org/10.1053/j.ajkd.2011.11.042 CrossRefPubMed
Foster MC, Inker LA, Hsu C-Y et al (2015) Filtration markers as predictors of ESRD and mortality in Southwestern American Indians with type 2 diabetes. Am J Kidney Dis 66(1):75–83. https://doi.org/10.1053/j.ajkd.2015.01.013 CrossRefPubMedPubMedCentral
Alter ML, Kretschmer A, Von Websky K et al (2012) Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab 58(7–8):659–671 PubMed
Abd El Dayem S, El Bohy AEM, El Shehaby A (2016) Value of the intrarenal arterial resistivity indices and different renal biomarkers for early identification of diabetic nephropathy in type 1 diabetic patients. J Pediatr Endocrinol Metab 29(3):273–279. https://doi.org/10.1515/jpem-2014-0397 CrossRefPubMed
National Institute for Health and Care Excellence (2010). Chronic heart failure in adults: management. Clinical guidelines [CG108]. Available from https://www.nice.org.uk/guidance/cg108
Gerstein HC, Pare G, McQueen MJ et al (2015) Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. Circulation 132(24):2297–2304. https://doi.org/10.1161/CIRCULATIONAHA.115.015744 CrossRefPubMed
Levey AS, Inker LA, Matsushita K et al (2014) GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64(6):821–835. https://doi.org/10.1053/j.ajkd.2014.07.030 CrossRefPubMed
Inker LA, Levey AS, Coresh J (2018) Estimated glomerular filtration rate from a panel of filtration markers—hope for increased accuracy beyond measured glomerular filtration rate? Adv Chronic Kidney Dis 25(1):67–75. https://doi.org/10.1053/j.ackd.2017.10.004 CrossRefPubMed
- Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes
Helen C. Looker
Colin N. A. Palmer
Mary Julia Brosnan
R. Neil Dalton
Paul M. McKeigue
Helen M. Colhoun
on behalf of the SUMMIT Investigators
- Springer Berlin Heidelberg
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II